We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+28.76%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$361M
AUM Growth
+$55.4M
(+18%)
Cap. Flow
+$39.7M
Cap. Flow
% of AUM
10.98%
Top 10 Holdings %
Top 10 Hldgs %
40.07%
Holding
85
New
33
Increased
24
Reduced
13
Closed
13
Top Buys
| 1 |
MoonLake Immunotherapeutics
MLTX
|
+$11.9M |
| 2 |
TG Therapeutics
TGTX
|
+$9.16M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$8.29M |
| 4 |
Roivant Sciences
ROIV
|
+$7.55M |
| 5 |
Viridian Therapeutics
VRDN
|
+$6.3M |
Top Sells
| 1 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$6.76M |
| 2 |
argenx
ARGX
|
+$5.71M |
| 3 |
Krystal Biotech
KRYS
|
+$5M |
| 4 |
Structure Therapeutics
GPCR
|
+$3.16M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$2.74M |
Sector Composition
| 1 | Healthcare | 85.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Natera
NTRA
$38.9B
| $2.29M | 0.63% |
25,000
-10,000
| -29% | -$752K |
|
52
Olema Pharmaceuticals
OLMA
$1B
| $2.26M | 0.63% |
+200,000
| New | +$2.58M |
|
53
Corbus Pharmaceuticals
CRBP
$167M
| $2.23M | 0.62% |
+56,941
| New | +$1.4M |
|
|
RVNC
54
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.21M | 0.61% |
450,000
+75,000
| +20% | +$444K |
|
55
Protagonist Therapeutics
PTGX
$9.06B
| $2.17M | 0.6% |
75,000
-50,000
| -40% | -$1.36M |
|
56
EyePoint Inc
EYPT
$1.12B
| $1.86M | 0.51% |
90,000
-75,000
| -45% | -$1.86M |
|
57
Madrigal Pharmaceuticals
MDGL
$12.8B
| $1.74M | 0.48% |
6,500
-8,500
| -57% | -$2M |
|
58
Arvinas
ARVN
$517M
| $1.65M | 0.46% |
40,000
-19,250
| -32% | -$841K |
|
|
ATXS
59
DELISTED
Astria Therapeutics
ATXS
| $1.62M | 0.45% |
115,000
-220,000
| -66% | -$2.74M |
|
60
Larimar Therapeutics
LRMR
$384M
| $1.6M | 0.44% |
+210,603
| New | +$1.64M |
|
61
Cytokinetics
CYTK
$10.9B
| $1.4M | 0.39% |
20,000
+10,000
| +100% | +$773K |
|
62
CytomX Therapeutics
CTMX
$788M
| $1.31M | 0.36% |
+600,000
| New | +$1.11M |
|
|
ELEV
63
DELISTED
Elevation Oncology
ELEV
| $1.28M | 0.36% |
+250,000
| New | +$810K |
|
64
Neurogene
NGNE
$744M
| $1.27M | 0.35% |
+25,000
| New | +$835K |
|
65
Sagimet Biosciences
SGMT
$483M
| $1.22M | 0.34% |
+225,000
| New | +$1.62M |
|
|
ATYR
66
aTyr Pharma
ATYR
$50M
| $1.17M | 0.32% |
+600,000
| New | +$1.05M |
|
67
PMV Pharmaceuticals
PMVP
$71.5M
| $1.15M | 0.32% |
675,000
-50,000
| -7% | -$93.4K |
|
68
Arrowhead Research
ARWR
$10.5B
| $1M | 0.28% |
+35,000
| New | +$1.12M |
|
69
Ultragenyx Pharmaceutical
RARE
$2.88B
| $934K | 0.26% |
+20,000
| New | +$943K |
|
70
uniQure
QURE
$2.77B
| $858K | 0.24% |
165,000
| – | – |
|
71
AN2 Therapeutics
ANTX
$169M
| $713K | 0.2% |
+219,331
| New | +$2.39M |
|
72
Intellia Therapeutics
NTLA
$1.59B
| $688K | 0.19% |
+25,000
| New | +$694K |
|
73
CALL
Amylyx Pharmaceuticals
AMLX
$1.97B
| – | – |
-200,000
| Closed | -$2.94M |
|
|
APLS
74
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-100,000
| Closed | -$5.99M |
|
|
75
argenx
ARGX
$53.8B
| – | – |
-15,000
| Closed | -$5.71M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2024 Portfolio in Review
As of Q1 2024, Ghost Tree Capital held 85 positions worth $361M, up 18% from $306M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Ghost Tree Capital deployed $39.7M of net new capital in Q1 2024, opening 33 new positions and adding to 24 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 130,000 shares worth $7.64M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 56% a quarter earlier.
On the sell side, the largest reduction was Krystal Biotech, an estimated $5M trimmed.
- Ghost Tree Capital's largest Q1 2024 buy was Apellis Pharmaceuticals: 130,000 shares worth $7.64M.
- Ghost Tree Capital added most to MoonLake Immunotherapeutics in Q1 2024, an estimated $11.9M increase.
- Ghost Tree Capital's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $5M.
- Ghost Tree Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $6.76M.
- Ghost Tree Capital's ten largest holdings make up 40% of its $361M portfolio in Q1 2024.
- Ghost Tree Capital opened 33 new positions and closed 13 in Q1 2024.
- Ghost Tree Capital's portfolio value rose 18% quarter-over-quarter to $361M.
Based on Ghost Tree Capital's 13F filing for Q1 2024, filed 15 May 2024.